Phase 2B Study in CHF (REC-DUT-003)
The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with chronic heart failure.
Status of Study
Planned to start in 2021.
Study Design
The double-blind, randomized, placebo-controlled study (Phase 2B) will evaluate both safety and efficacy of dutogliptin in combination with G-CSF as an adjunct treatment for patients with chronic heart failure.